Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Anticancer Res. 2021 Apr;41(4):2093-2100. doi: 10.21873/anticanres.14980.
BACKGROUND/AIM: The Renin-Angiotensin system (RAS) induces immunosuppression in the tumor microenvironment, and RAS inhibitors (RASi) improve the tumor immune microenvironment. We evaluated the impact of RASi on the efficacy anti-programmed cell death-1/Ligand-1 (anti-PD-1/PD-L1) antibodies.
This retrospective study analyzed non-small cell lung cancer (NSCLC) patients who received anti-PD-1/PD-L1 antibodies monotherapy as second- or later-line treatment. We classified patients into those with or without use of RASi.
A total of 256 NSCLC patients were included and 37 patients used RASi. The median PFS of patients treated with RASi was significantly longer than that of patients treated without (HR=0.59, 95%CI=0.40-0.88). The median OS of patients treated with RASi tended to be longer than that of patients treated without (HR=0.71, 95%CI=0.45-1.11).
The use of RASi was associated with a significantly longer PFS in NSCLC patients treated with anti-PD-1/PD-L1 antibodies. RASi use may enhance the efficacy of anti-PD-1/PD-L1 antibodies.
背景/目的：肾素-血管紧张素系统（RAS）在肿瘤微环境中诱导免疫抑制，而 RAS 抑制剂（RASi）可改善肿瘤免疫微环境。我们评估了 RASi 对程序性细胞死亡-1/配体-1（抗 PD-1/PD-L1）抗体疗效的影响。
本回顾性研究分析了接受抗 PD-1/PD-L1 抗体单药二线或以上治疗的非小细胞肺癌（NSCLC）患者。我们将患者分为使用 RASi 与未使用 RASi 两组。
共纳入 256 例 NSCLC 患者，其中 37 例患者使用 RASi。使用 RASi 的患者中位 PFS 明显长于未使用的患者（HR=0.59，95%CI=0.40-0.88）。使用 RASi 的患者中位 OS 有长于未使用的趋势（HR=0.71，95%CI=0.45-1.11）。
在接受抗 PD-1/PD-L1 抗体治疗的 NSCLC 患者中，使用 RASi 与 PFS 明显延长相关。RASi 的使用可能增强抗 PD-1/PD-L1 抗体的疗效。
